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Summary
 
Interleukin (IL)-10 is a pleiotropic cytokine which inhibits a broad array of immune parameters
including T helper cell type 1 (Th1) cytokine production, antigen presentation, and antigen-
specific T cell proliferation. To understand the consequences of altered expression of IL-10 in
immune models of autoimmune disease, the response to infectious agents, and the response to
tumors, we developed transgenic mice expressing IL-10 under the control of the IL-2 pro-
moter. Upon in vitro stimulation, spleen cells from unimmunized transgenic mice secrete
higher levels of IL-10 and lower amounts of IFN-
 

 
 than do controls, although no gross abnor-
malities were detected in lymphocyte populations or serum Ig levels. Transfer of normally patho-
genic CD4
 

 
 CD45RB
 
high
 
 splenic T cells from IL-10 transgenic mice did not cause colitis in re-
cipient severe combined immunodeficiency mice. Furthermore, co-transfer of these transgenic
cells with CD4
 

 
 CD45RB
 
high
 
 T cells from control mice prevented disease. Transgenic mice
retained their resistance to 
 
Leishmania major
 
 infection, indicating that their cell-mediated im-
mune responses were not globally suppressed. Lastly, in comparison to controls, IL-10 trans-
genic mice were unable to limit the growth of immunogenic tumors. Administration of block-
ing IL-10 mAbs restored in vivo antitumor responses in the transgenic mice. These results
demonstrate that a single alteration in the T cell cytokine profile can lead to dramatic changes
in immune responses in a manner that is stimulus dependent. These mice will be useful in de-
fining differences in inflammatory conditions and cellular immunity mediated by IL-10.
 
C
 
ytokines are secreted upon activation of immune cells
and are important in regulating immune responses.
Mouse CD4
 

 
 T cells can be divided into at least two sub-
sets. Although Th1 lymphocytes promote cellular immu-
nity by producing IL-2 and IFN-
 

 
, Th2 lymphocytes pro-
duce IL-4, -5, and -10, leading to augmented humoral
immunity and suppression of cellular immune responses
(1). IL-10 was first characterized as a product of Th2 clones
that could inhibit the synthesis of cytokines, such as IFN-
 

 
,
by Th1 clones (2). This inhibition of Th1 activity can lead
to an alteration in the Th1–Th2 balance, although IL-10
does not directly promote Th2 development (3, 4). Most
studies indicate that IL-10 acts on T cells indirectly by re-
ducing the expression of costimulatory molecules and cyto-
kines by APC, including macrophages and dendritic cells
(5–8). By this mechanism, IL-10 can inhibit IL-12 produc-
tion during a primary antigen stimulus, which in turn in-
hibits IFN-
 

 
 secretion and subsequently prevents the de-
velopment of Th1 cells and a cell-mediated immune response.
IL-10 is not expressed exclusively by Th2 cells, but also by
other T cells, B lymphomas, Ly-1 B cells, keratinocytes,
activated macrophages, and mast cell lines (3, 9). Consistent
with this broader expression pattern, IL-10 was found to
have additional activities including costimulation of thy-
mocyte and mast cell proliferation (3, 9).
Most research focused on investigating the role of IL-10
in cell-mediated and humoral immunity has involved ad-
ministering neutralizing antibodies or large amounts of IL-10
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to experimental animals or cultured cells (3, 9). While these
studies are helpful in broadly defining the function of IL-10,
it is difficult to regulate cytokine dose and timing by these
means. To determine the effects of an altered pattern and
increased IL-10 synthesis in vivo, we generated IL-10 trans-
genic mice in which mouse IL-10 is driven by the T cell–
specific human IL-2 promoter. The T lymphocytes that
synthesize transgene-derived mouse IL-10 in this model
should include the precursors of polarized Th1 and Th2
cells, as well as any IL-2–producing Th1 cells that can de-
velop in these mice. The transgenic mice were used to
characterize the role of IL-10 in vivo in an autoimmune
disease model, in the response to an infectious agent, and in
the rejection of tumor cells.
 
Materials and Methods
 
Mice.
 
The human IL-2 promoter–enhancer region from 
 

 
567
to 
 

 
54, relative to the transcriptional start site, was cloned up-
stream of the mouse IL-10 genomic sequence. The mouse IL-10
sequence used in the construct corresponds to positions 1,568–
6,879 of a 7.2-kb BglII fragment, in which position 1,568 repre-
sents nucleotide 16 of the cDNA (10). Transgenic mice were
made by standard methods at the University of California at Los
Angeles Transgenic Mouse Core Facility (Los Angeles, CA). The
construct was injected into eggs from (C57BL/6 
 

 
 C3H)F1 fe-
males mated to C57BL/6 males, and transgenic founders were
backcrossed onto the C57BL/6 background 
 

 
5 times. Four trans-
genic lines were initially characterized and two were selected for
this study, lines 9 and 14. Presence of the transgene was confirmed
using Southern blot analysis with the Genius nonradioactive de-
tection kit, which uses random-primed probes labeled with digoxi-
genin-dUTP (Boehringer Mannheim, Indianapolis, IN). C57BL/6
mice, from stock obtained from Simonsen Laboratories (Gilroy,
CA), and the transgenic mice lines were bred at our facility in the
University of California at Los Angeles vivarium. The mice are
kept in specific pathogen-free conditions and housed in microiso-
lator cages. C57BL/6 
 
scid
 
/
 
scid
 
 (SCID) mice are from Jackson Lab-
oratory (Bar Harbor, ME) and they are kept in a separate patho-
gen-free facility with filtered air flow and autoclaved food and
water.
 
Cell Culture.
 
Spleen cells were depleted of red blood cells by
hypotonic lysis, and suspensions of splenocytes and thymocytes
were cultured in RPMI supplemented with 10% FCS (JRH Bio-
sciences, Lenexa, KS), nonessential amino acids (Irvine Scientific,
Santa Ana, CA), sodium pyruvate (Irvine Scientific), penicillin,
streptomycin, 
 
l
 
-glutamine (Irvine Scientific), and 2-mercaptoeth-
anol. For cytokine detection, cells were plated out on 24-well
plates that were coated with 10–15 
 

 
g/ml anti-CD3
 

 
 (2C11) at a
concentration of 10
 
6
 
 cells/well. Supernatants from the cultures
were harvested at 72 h, pooled, and used in ELISA.
 
Cytokine Detection.
 
Cytokine levels in culture supernatants
were detected by a standard two-site sandwich ELISA for cyto-
kines as described in the PharMingen (San Diego, CA) manual,
except for a few alterations. High binding enzyme-linked immu-
noassay/radioimmunoassay Costar (Cambridge, MA) plates were
coated overnight with the following antibodies from PharMingen:
anti–mouse IL-10 (JES-2A5, 4 
 

 
g/ml) and IFN-
 

 
 (R4-6A2, 2 
 

 
g/
ml). Bound cytokine was detected with the following biotiny-
lated antibodies: anti–mouse IL-10 (SXC-1, 1 
 

 
g/ml) and IFN-
 

 
(XMG1.2, 1 
 

 
g/ml). Horseradish peroxidase (CALTAG Labs.,
South San Francisco, CA) and 2,2-azino-di(3-ethylbenzthiazoline
sulfonate) substrate reagents (Kirkegaarde & Perry Labs., Gaithers-
burg, MD) were used for visualization in a spectrophotometer.
Samples were assayed in triplicate in most cases, and were quanti-
tated by comparison with standard curves of purified recombinant
cytokines (PharMingen).
 
Serum Ig Analysis.
 
Serum samples were assayed for Ig con-
centration by a two-site sandwich ELISA as described, with some
minor alterations (PharMingen). For coating, unconjugated anti-
IgG1 (G1-6.5, 8 
 

 
g/ml) and anti-IgG2a (R19-15, 2 
 

 
g/ml) were
used. Detection for IgG1 and IgG2a was done using a 
 
	
 
 light
chain antibody conjugated to biotin (R8140, 2 
 

 
g/ml, 1 
 

 
g/ml,
respectively) and visualized as described for cytokine ELISAs. IgG
and IgM ELISAs are described in detail elsewhere (11). Samples
were assayed in triplicate and were quantitated by comparison
with the recommended Ig standards.
 
Flow Cytometry.
 
For analysis, purified cells from the spleen
and thymus were stained with monoclonal antibodies to CD4
(L3T4) conjugated to PE or biotin, biotin-CD8
 


 
 (Ly-2), PE-
CD45RB/220 (RA3-6B2), biotin-IgM (R6-60.2) (all from Phar-
Mingen), and Streptavidin-Tri-Color
 

 
 (CALTAG). Flow cyto-
metric analysis was performed on a FACScan
 

 
 flow cytometer
(Becton Dickinson, San Jose, CA) in the University of California
at Los Angeles Jonsson Cancer Center Flow Cytometry Core Fa-
cility. Cells were identified as lymphocytes by gating based on
forward and side scatter profiles. Between 3,000 and 5,000 gated
events were collected and analyzed using CellQuest software
(Becton Dickinson). Sorting for CD4
 

 
 CD45RB
 
high
 
 populations
used spleen cells stained with PE-CD45RB (16A) and FITC-
CD4. Cells were sorted using a FACstar Plus
 

 
 cell sorter in the
Jonsson Cancer Center Flow Cytometry Core Facility and Lysis
II software (Becton Dickinson). Cells were selected for being
positive for CD4 and high for CD45RB, the brightest staining
40% of the CD4
 

 
, CD45RB positive cells. Sorted populations
were 
 

 
98% pure upon postsort analysis.
 
Colitis Induction.
 
200 
 

 
l of 1
 

 
 PBS containing 4–5 
 

 
 10
 
5
 
sorted CD45RB
 
high
 
 CD4
 

 
 cells from IL-10 transgenic or control
mice were injected intraperitoneally into three to four C57BL/6
SCID mice aged 6–12 wk. Weight gain/loss, as a percentage of
original starting weight, was scored weekly for 8–12 wk. For sta-
tistical significance, regression analysis was performed comparing
data from recipients of either IL-10 transgenic or nontransgenic T
cells. For co-transfer studies, 2 
 

 
 10
 
5
 
 CD4
 

 
 CD45RB
 
high
 
 T cells
from IL-10 transgenic mice were mixed with 4 
 

 
 10
 
5
 
 cells from
the corresponding population from nontransgenic littermates, in-
jected into SCID recipients, and the recipient mice were evalu-
ated for colitis as described above. For preparation of tissue for
histopathologic analysis, 
 

 
3-mm segments of the distal large in-
testine were removed and fixed in a solution of 10% formalin.
Fixed tissues were embedded in paraffin and sections were pre-
pared and stained with hematoxylin and eosin. Sections were
graded in a blinded fashion by the same pathologist (S. Binder). A
scoring system, described previously (12), was established to com-
pare the histopathologic changes that occurred in the intestine as
a result of transferring the CD45RB
 
high
 
 CD4
 

 
 lymphocytes. The
following parameters weare used: (
 
a
 
) degree of inflammatory infil-
trate in the lamina propria was scored 0–3, (
 
b
 
) mucin depletion 0–3,
(
 
c
 
) reactive epithelial hyperplasia/atypia, 0–3, (
 
d
 
) number of in-
traepithelial lymphocytes in the epithelial crypts 0–3, and (
 
e
 
)
number of inflammatory foci/10 high-powered fields examined
1–3. Severity of the inflammatory changes was based on the sum
of the scores of these parameters with a higher score indicating a
greater inflammatory change.
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Leishmania Infection.
 
4–6 mice/group were infected in the
hind footpads with 2 
 

 
 10
 
5
 
 metacyclic promastigotes of 
 
Leishmania
major
 
 (strain WHOM/IR/-/173), and the size of the local lesion
monitored using a metric caliper. Parasite burden in the footpad
was determined at the end of the experiment by limiting dilution
(13). In brief, serial 10-fold dilutions of homogenates from in-
fected footpads were cultured in triplicate and examined after 2 wk
for the presence of motile promastigotes using inverted micros-
copy. Data were expressed as the mean titer (log
 
10
 
) of the last pos-
itive dilution of footpad homogenate. Cytokine production by
individual lymphocytes after 
 
L. major
 
 infection was assessed using
an ELISPOT assay as described previously (14). Single-cell sus-
pensions were prepared from popliteal LN and distributed in du-
plicate aliquots to 96-well plates coated with the appropriate anti-
cytokine antibody. Cytokine-secreting cells were detected using
biotinylated anticytokine antibodies and streptavidin alkaline phos-
phatase. Color was developed using 5-bromo-4-chloro-3-indolyl
phosphate in 0.1 M 2-amino-2-methyl-1-propanol buffer sus-
pended in agarose. After solidification, individual blue spots were
counted using inverted microscopy.
 
Tumor Challenge.
 
Lewis lung (3LL) carcinoma cells were cul-
tured in RPMI supplemented as described in cell culture meth-
ods. Before injection, cells were trypsinized and washed twice in
1
 

 
 PBS. To establish the tumors in vivo, groups of 9–14 mice
were injected subcutaneously with 5 
 

 
 10
 
5
 
 3LL cells. Cross-sec-
tional diameter measurements were taken with calipers and tumor
growth recorded daily. For antibody blocking studies, groups of
3–4 mice were injected with 5 
 

 
 10
 
5
 
 3LL cells. 1.5 mg of anti–
IL-10 antibody JES-2A5 or control isotype matched antibody
GL113-5E7 were administered intraperitoneally 24 h before and
4 d after tumor inoculation.
 
Results
 
Lymphocytes from IL-10 Transgenic Mice Secrete Increased
Levels of IL-10.
 
Because Thp and Th0 precursor cells syn-
thesize IL-2 upon activation, the IL-2 promoter in the
transgenic construct should permit T cell–specific expres-
sion of IL-10 from the earliest stages of T cell stimulation
(15). IL-2 promoter fragments have been used previously to
direct gene expression by activated T cells in transgenic
mice (16–19). The promoter fragment we used is almost
identical to that used in another transgenic mouse model,
in which T cell–specific expression of lacZ was obtained
(19). Furthermore, transient transfectants of Jurkat cells
bearing this construct could be induced to synthesize IL-10
after stimulation with phorbol ester and calcium ionophore
(Wei, S.H.-Y., and K.W. Moore, unpublished data). To as-
sess the effect of the transgene on cytokine production by
lymphocytes, IL-10 transgenic mice were analyzed for cy-
tokine levels. IL-10 was not detectable in the serum of un-
immunized transgenic mice by ELISA. Splenocytes from
line 9 or line 14 IL-10 transgenic and nontransgenic litter-
mates were stimulated with polyvalent anti-CD3
 

 
 mAb,
and the culture supernatants were used in ELISAs to mea-
sure IFN-
 

 
 and IL-10. As seen in Fig. 1, 
 
A
 
 and 
 
B
 
, spleen
cells from IL-10 transgenic mice produce up to three times
more IL-10 and approximately threefold reduced levels of
IFN-
 

 
, when compared to control littermates. Two other
lines of IL-10 transgenic mice gave similar increases in IL-10
and decreases in IFN-
 

 
 levels (Hagenbaugh, A., data not
shown). IL-4 could not be detected from the cultures of
stimulated splenocytes from either transgenic mice or non-
transgenic littermates, suggesting that the IL-10 transgene
did not cause a great increase in Th2 activity. IL-4 could be
detected from thymocytes cultured in parallel, providing a
positive control for the T cell stimulation and IL-4 ELISA
(Hagenbaugh, A., data not shown). These data indicate that
IL-10 secretion by cells from the transgenic mice leads to a
decrease of the prototypical Th1 cytokine IFN-
 

 
.
 
IL-10 Transgenic Mice Have Normal T and B Lymphocyte
Development.
 
To determine if altered IL-10 secretion leads
to abnormal lymphocyte development or activity in trans-
genic mice, we analyzed lymphoid organs for cell number
and phenotype. As summarized in Table 1, flow cytometry
profiles from the spleen and thymus of line 9 IL-10 trans-
genic mice show no changes in the percentages of CD4
 

 
,
CD8
 

 
, or double-positive T cell subsets. Cell numbers for
spleen and thymus preparations were normal. In addition,
B cell numbers were not altered, as B220 plus surface IgM
profiles show no difference between IL-10 transgenic mice
and littermate controls. Similar data were obtained from
line 14 IL-10 transgenic mice (Hagenbaugh, A., data not
shown).
Because Th2 cytokines are involved in class switching of
antibodies to producte of the 
 

 
 and 
 

 
1 heavy chains, IL-10
transgenic mice were analyzed for serum Ig isotypes. Serum
samples from IL-10 transgenic and littermate control mice
were used in ELISAs for total IgG, IgM, IgG1, IgG2a, and
IgE. The levels of total IgG and IgM were not significantly
different between IL-10 transgenic and control mice, with
the averages for both IgG and IgM virtually identical be-
tween the two groups (Fig. 2). There was a slight increase
in the serum levels of both IgG1 and IgG2a isotypes in the
IL-10 transgenic mice, which was not significant. IgE could
not be detected by ELISA in the serum of either sets of mice
(Hagenbaugh, A., data not shown). Thus, altered IL-10 ex-
pression in the IL-10 transgenic mice does not detectably
effect Th2-specific class switching.
Figure 1. Altered cytokine secretion in IL-10 transgenic mice. Spleen
cells from two lines of IL-10 transgenic mice and control littermates were
isolated and stimulated on anti-CD3 coated plates. Supernatants were
tested for the presence of IL-10 (A) and IFN- (B) by ELISA. Results are
represented as the mean  SE, with the mean indicated above the error
bar. 3–5 mice were tested in each group.
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IL-10 Transgenic Spleen Cells Prevent Colitis Induction. To
determine the effect of altered IL-10 expression in the
transgenic mice on Th1 cytokine synthesis during an in
vivo immune response, we investigated a colitis model de-
pendent upon the secretion of IFN- and TNF-
 for
pathogenesis. Transfer of CD4 CD45RBhigh splenic T
cells to SCID or RAG-2/ immune-deficient recipients
leads to a wasting disease that is characterized by Th1 cy-
tokine release and inflammation of the large intestine,
which might be similar to inflammatory bowel disease in
humans (20–23). Recipients of control CD4 CD45RBhigh
splenic T cells followed a typical course of disease, losing
weight at about 4 wk and remaining sick for the duration
of the study (Fig. 3). These mice required killing by 9 wk
after transfer, as they developed a hunched appearance and
piloerection of the coat. By contrast, the recipients of
CD4 CD45RBhigh T cells from the IL-10 transgenic mice
gained weight early on, and were able to maintain their
weight for the entire experiment (Fig. 3). No other signs of
illness were seen in recipients of T cells from the transgenic
mice throughout the course of the study. Histological anal-
ysis indicates that the large intestines of recipients of CD4
CD45RBhigh T cells from nontransgenic littermates have
the typical hallmarks of inflammation of this model, con-
sisting of lymphocyte infiltration, epithelial hyperplasia, and
loss of goblet cells (Fig. 4 A). The recipients of IL-10 trans-
genic T lymphocytes have virtually normal large intestines
(Fig. 4 B). The average histological scores were evaluated as
described previously (12) and in Materials and Methods.
For the distal colon of recipients of nontransgenic T cells,
the score was 13.5 out of a possible 15 (n  4). The score
was 4.5 for the recipients of IL-10 transgenic T cells (n  3),
which is similar to that of normal mouse distal colon (12).
Preparations of the small and large intestinal lamina propria
lymphocytes and intraepithelial lymphocyte populations of
the SCID recipients revealed numbers of IL-10 transgenic
derived lymphocytes comparable to that after transfer of
nontransgenic T cells (Hagenbaugh, A., data not shown).
These data indicated that the CD4 CD45RBhigh T cells
from IL-10 transgenic mice were not impaired in their
ability to colonize the SCID intestine.
Table 1. T and B Lymphocyte Differentiation Is Normal in IL-10 Transgenic Mice
Mouse type Cell no. CD4 CD8 CD4/CD8 B220/IgM
Thymus % % % %
Control No. 1 1  108 9.8 2.6 83.7 –
Control No. 2 1.2  108 10.9 2.6 82.7 –
IL-10 Tg No. 1 9.8  107 10.4 3.2 82.1 –
IL-10 Tg No. 2 1.6  108 15.3 3.4 77.4 –
Spleen
Control No. 1 4.8  107 26.6 17.5 1 60.8
Control No. 3 5.5  107 22.8 9.7 1 61.8
Control No. 4 5.4  107 19.5 14.4 1 60.3
IL-10 Tg No. 1 3.0  107 22.8 13.2 1 62.8
IL-10 Tg No. 2 3.0  107 24.9 13.2 1 58.4
IL-10 Tg No. 3 6.5  107 16.5 10.3 1 63.7
IL-10 Tg No. 4 6.5  107 23.4 14.6 1 50.5
Cells from spleen and thymus of line 9 IL-10 transgenic (Tg) mice were prepared, counted, and stained with the various cell-surface markers. Stained
cells were analyzed by flow cytometry as described in Materials and Methods. Values are given as percentages of total gated lymphocyte populations,
based on light scatter. –, not done.
Figure 2. Ig levels are not altered in IL-10 transgenic mice. Serum
samples from line 9 IL-10 transgenic (filled circles) and control littermate
(open circles) mice were assayed for the indicated Ig isotypes by ELISA.
The group of mice analyzed for IgM and total IgG was separate from the
group used for IgG1 and IgG2a analysis. The average concentration in
micrograms per milliliter for each isotype is indicated in parentheses. Each
symbol represents data from one individual mouse.
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Previous studies have shown that co-transfer of CD4
CD45RBlow T cells with the corresponding CD45RBhigh
pathogenic population is protective, and these CD45RBlow
T cells may prevent disease by production of cytokines that
inhibit the development or function of Th1 and inflamma-
tory cells (20, 22). To determine if CD4 CD45RBhigh
T cells from the IL-10 transgenic mice are merely incapable
of causing disease, or if altered IL-10 secretion converts them
to a suppressive population similar to CD45RBlow T lym-
phocytes, co-transfers of IL-10 transgenic and nontrans-
genic CD4 CD45RBhigh splenic T cells were carried out.
As can be seen from Fig. 5, there was no weight loss in co-
transfer recipients, demonstrating that CD4 CD45RBhigh
T cells from the IL-10 transgenic mice can actively prevent
colitis induction by pathogenic Th1 lymphocytes.
IL-10 Transgenic Mice are Resistant to L. Major Infection.
L. major infection of inbred mouse strains remains a well-
characterized model for control of Th1 and Th2 differenti-
ation in vivo. Mouse strains including C57BL/6 and B10.D2
mount a healing Th1 response to the parasite, whereas
BALB/c mice mount a nonhealing Th2 response (24). IL-10
transgenic mice are on the healing C57BL/6 background.
To determine if altered expression of IL-10 by T cells can
affect this ability to mount a protective Th1 response, IL-10
transgenic, along with control B10.D2 and BALB/c mice,
were infected with L. major. As assessed by lesion size and
parasite burden after 10 wk, IL-10 transgenic mice con-
trolled infection in a manner comparable to resistant
B10.D2 mice (Fig. 6 A). As described previously, BALB/c
mice were unable to clear the parasite. ELISPOT analysis
of cytokines from peripheral lymph node cells from in-
fected IL-10 transgenic mice were consistent with the differ-
entiation of Th1 effector cells, in contrast with the differen-
tiation of Th2 effector cells that occurred in the susceptible
BALB/c mice (Fig. 6 B).
Antitumor Reactivity is Decreased in IL-10 Transgenic Mice.
It has been demonstrated that IL-10 is present in the local
tumor environment in nonsmall cell lung carcinomas
(NSCLCs)1 and other tumors, where this cytokine might
provide a mechanism for evasion of the local cell-mediated
immune response (25, 26). The mouse NSCLC 3LL has a
well-defined peptide antigen (27) which can be recognized
by CD8 T cells which are an important component of the
antitumor response. To further elucidate the role of local
IL-10 production in tumor rejection, IL-10 transgenic
mice were injected with 3LL cells and monitored for tu-
mor formation. In comparison to control littermates, IL-10
Figure 3. CD4 CD45RBhigh cells from IL-10 transgenic mice fail to
induce colitis in SCID recipients. 4–5  105 FACS sorted CD4
CD45RBhigh cells from IL-10 transgenic or control littermate mice were
injected into SCID mice. Weight gain/loss was scored weekly for 9 wk.
Values are shown as a percentage of original weight at day 0, the time of
cell injection. Number of mice in each group is indicated in parentheses.
Regression analysis of the two curves shown indicated the data to be
highly significant, P  0.0012. (Similar results were obtained using Rag-2/
mice as T cell recipients.)
Figure 4. Lack of intestinal inflammation in SCID recipients of CD4 CD45RBhigh T cells from IL-10 transgenic mice. Tissues from the distal colon
were stained with hematoxylin and eosin and scored as described in Materials and Methods. (A) Section of distal colon from a SCID recipient injected
with control CD4 CD45RBhigh T cells. Note the loss of goblet cells and disorganization of the epithelial cells. (B) Section of distal colon from a SCID
recipient injected with IL-10 transgenic, CD4 CD45RBhigh T cells. Original magnification, 78 for both sections.
1Abbreviation used in this paper: NSCLC, nonsmall cell lung carcinoma.
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transgenic mice developed relatively large tumors (Fig. 7
A). To assure that the effect observed was due to direct ac-
tion by IL-10, we used a monoclonal antibody known to
block IL-10 action. Injection of the JES-2A5 anti–IL-10
antibody at 24 h before and 4 d after tumor cell injection
enabled the IL-10 transgenic mice to control the growth of
transplanted tumors comparable to their nontransgenic lit-
termates (Fig. 7 B). Injection of the control isotype-matched
GL113 antibody had no effect on the susceptibility of the
IL-10 transgenic mice to 3LL tumor cells (Fig. 7 B). This
indicates that the production of IL-10 by infiltrating lym-
phocytes prevents the development of an effective immune
response against this tumor.
Discussion
We have described an in vivo model to assess the role of
IL-10 in the regulation of an immune response leading to
autoimmunity, as well as protective immune responses. By
using the human IL-2 promoter to drive mouse IL-10 cy-
tokine expression, transgene-derived IL-10 produced only
transiently in response to T cell activation. At the same
time, these transgenic mice have an increased population of
T cells that make IL-10 and should produce IL-10 earlier
in the immune response. We predicted that activated Th1
type T cells in the IL-10 transgenic mice would downregu-
late their own activity, including IL-10 secretion from the
transgene. Consistent with our expectations, polyclonally
activated splenic T cells from transgenic mice secreted two-
to fourfold increased levels of IL-10, as well as decreased
levels of IFN-. The IL-10 transgenic mice were otherwise
macroscopically normal, and did not exhibit any defects in
growth and development. The relatively subtle alterations
in cytokine production observed after polyclonal T cell ac-
tivation in the transgenic mice may reflect the activity of
naive T cells, which normally are capable of making only
low amounts of IL-2 (15). These subtle alterations, how-
ever, led to a dramatic decrease in the ability to mount cer-
tain immune responses under several circumstances de-
scribed below.
Consistent with their overall good health and develop-
ment, the immune system of the IL-10 transgenic mice is by
most measures not significantly different from the control
Figure 5. Co-transfer of CD4 CD45RBhigh T cells from IL-10 trans-
genic mice prevents colitis pathogenesis. 2  105 CD4 CD45RBhigh
T cells from IL-10 transgenic mice were co-injected with 4  105 cells of
the same type from control mice into SCID recipients. The recipients
were monitored weekly for weight loss as described in Fig. 3.
Figure 6. Resistance to L. major infection in IL-10 transgenic mice.
Groups of four to six IL-10 transgenic, B10.D2, and BALB/c mice were
inoculated in the rear footpads with promastigotes of L. major. (A) Data
represent the mean lesion size  SE for the indicated groups of mice
throughout infection. Parasite burden, representing the log10 of viable
Leishmania in cultured footpad homogenates after 10 wk, is indicated in
parentheses (see Materials and Methods). (B) Popliteal LN cells draining
the site of infection were used in ELISPOT assays for the detection of
IFN- and IL-4. Data represent the number of cytokine-producing cells
per LN  SE for designated mice after 10 wk of infection.
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littermates. T and B cell numbers and phenotype were nor-
mal. Although IL-10 is a potent downregulator of Th1 cy-
tokine production, IFN- synthesis is not eliminated in the
IL-10 transgenic mice. No major differences were apparent
in the serum Ig profiles either. We therefore conclude that
the amount of IL-10 synthesized in these mice is not suffi-
cient to cause either a complete suppression of Th1 cytokines
or immune dysfunction in unimmunized mice.
It is well documented that transfer of the CD4 CD45-
RBhigh T cell population of normal mice into SCID or
RAG-2/ mice causes severe inflammation in the large
intestine, mediated in part by secretion of TNF-
 and
IFN- (21, 23). We have shown that transfer of this same
population of T cells from the IL-10 transgenic mice does
not cause the wasting condition that accompanies this dis-
ease. Histological analysis confirmed that the recipients of
IL-10 transgenic T cells have few of the hallmarks of intes-
tinal inflammation which are typical of this model. We hy-
pothesize that production of IL-10 alters cytokine secretion
from the CD4 CD45RBhigh T cells, and thereby inhibits
their ability to cause disease. When CD4 CD45RBhigh
T cells from the IL-10 transgenic mice were co-transferred
with the corresponding pathogenic population from con-
trol animals, colitis pathogenesis was prevented. These data
suggest that the altered IL-10 secretion by the transgenic
T cells can control the production of inflammatory cyto-
kines by other cells. In other studies, IL-10/ mice sponta-
neously developed colitis (28), and transfer of unfraction-
ated lamina propria lymphocytes from IL-10/ mice into
RAG-2/ recipients gave rise to severe inflammation of
the colon (29). Together, these data indicate that T cell–
derived IL-10 is critical for regulating the cytokine balance
in the intestine that may lead to or prevent colitis patho-
genesis.
Our data are consistent with results from a previous re-
port in which transfer of CD4 CD45RBhigh cells into
SCID mice was accompanied by daily administration of re-
combinant IL-10 (21). This treatment prevented the devel-
opment of colitis and reduced the amount of IFN- in the
colon. However, the effects were short lived since these
mice developed colitis indistinguishable from controls 4 wk
after the last injection of rIL-10. The transient nature of the
effect of rIL-10 treatment could be due to the systemic dis-
tribution and rapid metabolism of the cytokine. These
problems would not have been expected in the transgenic
mouse model we describe here, and consistent with this,
disease was not observed in SCID recipients of IL-10 trans-
genic T cells up to 3 mo after transfer. In contrast to these
results, it was shown that co-transfer of CD4 CD45RBhigh
and CD45RBlow cells into SCID mice, along with anti–IL-10
blocking antibody, did not abolish the protective effect of
CD4 CD45RBlow T cells (22). Because, in our model,
Th1-produced IL-10 was sufficient to convert pathogenic
T cells to active inhibitors of colitis in co-transfer, we con-
clude that although the CD4 CD45RBlow T cells may use
IL-10 to suppress colitis, other IL-10–independent path-
ways exist in CD4 CD45RBlow T cells that may be capa-
ble of preventing disease.
Control of L. major infection in mice is mediated by
IFN-–producing Th1 cells that promote a cell-mediated
immune response. IL-10 transgenic mice on the healing
C57BL/6 genetic background developed Th1 responses to
L. major that were comparable to those in resistant B10.D2
mice. Thus, IL-10 secretion in these transgenic mice nei-
ther skewed cytokine production from T cells, nor inhib-
ited cell-mediated immune responses to the parasite. It is
not known why Th1 type cell-mediated responses are di-
minished in the colitis model but not in response to L. ma-
jor infection. The intracellular forms of the parasite induce
high levels of IL-12 (30), and the amount of transgene-derived
Figure 7. Uncontrolled tumor growth in IL-10 transgenic mice. (A) Groups of 9–14 IL-10 transgenic and control littermate mice were injected sub-
cutaneously with 3LL carcinoma cells. Tumor growth was recorded on a daily basis using metric calipers. Data are shown as the mean tumor volume for
each group of mice  SE at each indicated time point. This is representative of one of three experiments, which all yielded similar results. (B) 1.5 mg of
IL-10 neutralizing antibody, JES-2A5, or control isotype antibody, GL113-5E7, were administered intraperitoneally at 24 h before and 4 d after 3LL cell
injection to IL-10 transgenic mice. Control littermates were injected with 3LL cells as a negative control for tumor growth. Groups of three to four mice
were analyzed. Data is shown as mean tumor volume  SE.
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IL-10 produced under the control of the IL-2 promoter
may not be sufficient to overcome the activation of Th1
cells by the pathogen. Reconstitution of SCID mice with
L. major-specific CD4 CD45RBlow T cells conferred sus-
ceptibility to disease that could be reversed by anti–IL-4,
but not anti–IL-10 antibodies (22), consistent with studies
in both wild-type (31) and IL-4–deficient mice (32). Al-
though IL-10 can inhibit Th1 development and prolifera-
tion, IL-4 is critical for the differentiation of Th2 cells (33–
36). The lack of elevated IL-4 levels in the IL-10 transgenic
mice after infection presumably underlies the inability of
the transgenic mice to develop progressive disease. In sum-
mary, the data are consistent with previous information in-
dicating that IL-10 alone is not a key regulator of host re-
sponses to L. major.
Although tumors may express antigens, they often escape
the host’s immune surveillance. It is well known that tumor
cells have the capacity to mediate immunosuppression, in
part, through the elaboration of immune inhibitory cyto-
kines (25, 26). Not only may tumors directly suppress im-
mune responses, but they may also induce host immune
cells to release immunosuppressive cytokines. For example,
human NSCLC cells have been shown to cause a 10–100-
fold induction of lymphocyte-derived IL-10 (37). Thus,
because the IL-10 transgenic mice used in these studies
may parallel the apparent defect in response to lung cancer
in human patients, we hypothesized that these mice would
have a limited capacity to control tumor growth. For these
studies we used an immunogenic murine lung cancer, 3LL.
This tumor has a mutant connexin 37 gap junction protein,
and a peptide containing the mutated sequence is recog-
nized by anti-3LL CTL (27). Antitumor CTL are protective
against 3LL tumor challenge, suggesting that the cytotoxic
responses of CD8 T lymphocytes are important in limit-
ing tumor growth. To determine if lymphocyte-derived
IL-10 interfered with the host antitumor response, IL-10
transgenic and control mice were challenged with 3LL tu-
mor cells. IL-10 transgenic mice were unable to control tu-
mor growth, whereas control recipients showed tumor
progression at a significantly slower rate. The inability of the
IL-10 transgenic mice to limit 3LL tumor growth is due to the
secretion of IL-10, as administration of anti–IL-10–block-
ing antibody reduced tumor growth in the IL-10 transgenic
mice to that of control mice. These data demonstrate that
the effect of the IL-10 transgene is due directly to IL-10
action. Previously, only viral, but not mouse, IL-10 was
shown to be effective in preventing immune responses to
melanomas and sarcomas (38). There are several ways in
which altered expression of mouse IL-10 may have inhib-
ited an effective antitumor immune response. These include
the reduction of MHC class I expression (39) or costimula-
tory molecules (6), immune deviation (40), and induction
of anergy in responding T cells (40, 41). Further experiments
are required to characterize the mechanism for tumor un-
responsiveness in IL-10 transgenic mice, and to determine
if other Th1 or CD8 T cell responses are likewise sup-
pressed in these transgenic mice.
IL-10 previously has been implicated in the regulation of
a wide variety of inflammatory and other immune re-
sponses (3, 9, 42), but many of the studies have relied upon
the unphysiologic administration of exogenous IL-10. The
transgenic mice described here provide an important new
model for studying the role of T cell–derived IL-10 synthesis
in vivo. These mice have been backcrossed extensively
onto the C57BL/6 background, so that the IL-10 trans-
genic mice and their littermates are close to being isogenic
strains. Furthermore, IL-10 synthesis is transient and related
to T cell activation, thereby avoiding any potential toxic
effects of either constitutive expression of IL-10, or very
high levels of IL-10 over expression. Finally, evidence from
two models, a pathogenic immune response leading to
colitis and a beneficial immune response leading to tumor
rejection, demonstrates that some, but not all, cell-medi-
ated immune responses are profoundly altered in these
transgenic animals. Recently, IL-10 transgenic mice that
express cytokine under the control of the CD2 promoter
have been described (43). Consistent with the results de-
scribed here, these mice show some evidence of a sup-
pressed Th1 type response, as they are more susceptible to
infection with Mycobacterium tuberculosis. Additional experi-
ments now underway are designed to determine the mech-
anism for decreased colitis pathogenesis and tumor cell re-
jection in the IL-10 transgenic mice.
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